TEVA logo

TEVA
Teva- Pharmaceutical Industries Ltd. - ADR

26,881
Mkt Cap
$39.68B
Volume
2.71M
52W High
$37.35
52W Low
$14.99
PE Ratio
25.32
TEVA Fundamentals
Price
$34.07
Prev Close
$34.16
Open
$34.29
50D MA
$32.05
Beta
0.81
Avg. Volume
6.07M
EPS (Annual)
$1.22
P/B
4.82
Rev/Employee
$523,613.72
$49,934.02
Loading...
Loading...
News
all
press releases
TEVA's MAA for Olanzapine LAI in Schizophrenia Accepted in the EU
Teva aims to expand its schizophrenia portfolio after the EMA accepts its filing for olanzapine long-acting injectable (TEV-'749).
News Placeholder
More News
News Placeholder
Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.
News Placeholder
Teva Reports Gap In Tardive Dyskinesia Diagnosis Among Patients With Mood Disorders
(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) on Monday announced new real-world data from the IMPACT-TD Registry showing a significant gap in diagnosing tardive dyskinesia in patients with underlying mood disorders...
News Placeholder
Teva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx Deal
Teva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx Deal...
News Placeholder
Barclays Forecasts Strong Price Appreciation for Teva Pharmaceutical Industries (NYSE:TEVA) Stock
Barclays raised their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an "overweight" rating in a research note on Wednesday...
News Placeholder
Strs Ohio Cuts Stake in Teva Pharmaceutical Industries Ltd. $TEVA
Strs Ohio cut its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 25.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 566,561 shares of the company's stock after selling 1...
News Placeholder
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Moderate Buy" from Brokerages
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the ten research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and nine have assign...
News Placeholder
Teva Pharmaceutical Industries Q1 Earnings Call Highlights
Teva Pharmaceutical Industries (NYSE:TEVA) reported first-quarter 2026 results that management said reflected continued momentum in its innovative portfolio, while also outlining the company's first...
News Placeholder
Wall Street Zen Downgrades Teva Pharmaceutical Industries (NYSE:TEVA) to Hold
Wall Street Zen lowered Teva Pharmaceutical Industries from a 'strong-buy' rating to a 'hold' rating in a report on Saturday...
News Placeholder
75,000 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Purchased by Nkcfo LLC
Nkcfo LLC acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available